{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 367,
  "pageCount": 415,
  "prevPage": 366,
  "nextPage": 368,
  "slideType": "testimonial",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide highlights a direct contradiction between the company's marketing (Vykat) and expert clinical opinion.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/367",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-367",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "GLP-1's likely to work better for PWS than Vykat; \"really good results\"; excited about trials and other options vs. Vykat; Soleno already trying to market against GLP-1's",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b5-89ab868c2c39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "GLP-1's likely to work better for PWS than Vykat; “really good results”; excited about trials and other options vs. Vykat; Soleno already trying to market against GLP-1's",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebff0cda-9b8d-47e2-8fe9-746ae6cc8ecf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.53
      },
      "kind": "quote",
      "text": "The other thing that they talked about when the rep came was, they mentioned GLP-1s are maybe not a good option because these kids can express pain better and things. Obviously, from a diabetes and weight loss perspective, GLP-1s are probably better but they haven't done the trials yet. They did liraglutide trials. But they haven't done some of the newer GLP-1s that we know work better. I wonder about that in the future. And then there's the setmelanotide medication, which they do for other monogenic causes. Whether they do a trial with that. Also, the question just is, are there other options? And with GLP-1s, we know there's a lot of benefits for behaviors and brain stuff, so I think that would be fascinating to see in the future with the literature on addiction. You have to do the trials. But so, you do also wonder, will there be other options that people can use?.. And I've used some GLP-1s and had really good results. I will say the one thing is most people are pretty comfortable with GLP-1s...And just getting approval for obesity is not hard.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8d54262-7764-4aea-97be-844e6916bf08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Obviously, from a diabetes and weight loss perspective, GLP-1s are probably better but they haven't done the trials yet. They haven't done some of the newer GLP-1s that we know work better... the question just is, are there other options? And with GLP-1s, we know there's a lot of benefits for behaviors and brain stuff, so I think that would be fascinating to see in the future with the literature on addiction. You have to do the trials. But so, you do also wonder, will there be other options that people can use?.. And I've used some GLP-1s and had really good results. I will say the one thing is most people are pretty comfortable with GLP-1s... And just getting approval for obesity is not hard.\" — Pediatric endocrinologist at a Delaware academic center with eight endocrinologists and ~50 PWS patients",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b5-8f537ce6ca2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3452702a-f38b-476f-9f51-6dd6a97cf646",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Endocrinologist #4 is far more excited about GLP-1's in PWS than Vykat, dismissed the Vykat rep's argument against GLP-1's, and indicated his personal experience and the general results are “really good”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c1a3499-64ae-4e58-ae37-e49c8fff8ac6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}